389 related articles for article (PubMed ID: 26281838)
61. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
62. Hematopoietic Stem Cell Transplantation in T Cell and Natural Killer Cell Lymphomas: Update on Recent Advances.
Boo YL; Koh LP
Transplant Cell Ther; 2021 Jul; 27(7):571-588. PubMed ID: 33857661
[TBL] [Abstract][Full Text] [Related]
63. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
[TBL] [Abstract][Full Text] [Related]
64. The aggressive peripheral T-cell lymphomas: 2017.
Armitage JO
Am J Hematol; 2017 Jul; 92(7):706-715. PubMed ID: 28516671
[TBL] [Abstract][Full Text] [Related]
65. Aggressive T-cell lymphomas: 2021 Updates on diagnosis, risk stratification and management.
Zain JM; Hanona P
Am J Hematol; 2021 Aug; 96(8):1027-1046. PubMed ID: 34111312
[TBL] [Abstract][Full Text] [Related]
66. Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
Giulino-Roth L; Ricafort R; Kernan NA; Small TN; Trippett TM; Steinherz PG; Prockop SE; Scaradavou A; Chiu M; O'Reilly RJ; Boulad F
Pediatr Blood Cancer; 2013 Dec; 60(12):2018-24. PubMed ID: 24038967
[TBL] [Abstract][Full Text] [Related]
67. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Hosing C; Nieto YL; Oki Y
Br J Haematol; 2017 Mar; 176(5):750-758. PubMed ID: 27983760
[TBL] [Abstract][Full Text] [Related]
68. New perspectives in the therapeutic approach of peripheral T-cell lymphoma.
Gisselbrecht C; Sibon D
Curr Opin Oncol; 2018 Sep; 30(5):285-291. PubMed ID: 30096094
[TBL] [Abstract][Full Text] [Related]
69. Anaplastic large cell lymphoma, ALK-positive.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2012 Aug; 83(2):293-302. PubMed ID: 22440390
[TBL] [Abstract][Full Text] [Related]
70. Hematopoietic stem cell transplantation for non-Hodgkin lymphoma.
Bhatt VR; Vose JM
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1073-95. PubMed ID: 25459180
[TBL] [Abstract][Full Text] [Related]
71. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.
Van de Wyngaert Z; Coppo P; Cervera P; Fabiani B; Lemonnier MP; Corre E; Marjanovic Z; Aoudjhane M; Mohty M; Duléry R
Eur J Haematol; 2021 Apr; 106(4):467-472. PubMed ID: 33320379
[TBL] [Abstract][Full Text] [Related]
72. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
Broccoli A; Argnani L; Zinzani PL
Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
[TBL] [Abstract][Full Text] [Related]
73. Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review.
Yang YT; Tai CJ; Chen C; Wu HC; Mikhaylichenko N; Chiu HT; Chen YY; Hsu YE
PLoS One; 2016; 11(10):e0161811. PubMed ID: 27711130
[TBL] [Abstract][Full Text] [Related]
74. Allogeneic transplantation in T-cell lymphomas.
Schmitz N; Wu HS; Glass B
Semin Hematol; 2014 Jan; 51(1):67-72. PubMed ID: 24468318
[TBL] [Abstract][Full Text] [Related]
75. Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice.
O'Connor OA; Bhagat G; Ganapathi K; Pedersen MB; D'Amore F; Radeski D; Bates SE
Clin Cancer Res; 2014 Oct; 20(20):5240-54. PubMed ID: 25320373
[TBL] [Abstract][Full Text] [Related]
76. Peripheral T-cell lymphoma: autologous hematopoietic cell transplantation as first-line therapy.
Laport GG
Curr Opin Oncol; 2010 Sep; 22(5):409-13. PubMed ID: 20683269
[TBL] [Abstract][Full Text] [Related]
77. Peripheral T-cell lymphoma, not otherwise specified.
Broccoli A; Zinzani PL
Blood; 2017 Mar; 129(9):1103-1112. PubMed ID: 28115372
[TBL] [Abstract][Full Text] [Related]
78. Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment.
Merdin A; İskender D; Ulu BU; Doğan M; Çakar MK; Dal MS; Altuntaş F
Medicine (Baltimore); 2019 Jul; 98(30):e16482. PubMed ID: 31348254
[TBL] [Abstract][Full Text] [Related]
79. Non-anaplastic peripheral T cell lymphoma in children and adolescents-an international review of 143 cases.
Mellgren K; Attarbaschi A; Abla O; Alexander S; Bomken S; Bubanska E; Chiang A; Csóka M; Fedorova A; Kabickova E; Kapuscinska-Kemblowska L; Kobayashi R; Krenova Z; Meyer-Wentrup F; Miakova N; Pillon M; Plat G; Uyttebroeck A; Williams D; Wróbel G; Kontny U;
Ann Hematol; 2016 Aug; 95(8):1295-305. PubMed ID: 27270301
[TBL] [Abstract][Full Text] [Related]
80. Peripheral T-cell lymphoma in children and adolescents: a single-institution experience.
Al Mahmoud R; Weitzman S; Schechter T; Ngan B; Abdelhaleem M; Alexander S
J Pediatr Hematol Oncol; 2012 Nov; 34(8):611-6. PubMed ID: 23042011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]